QED Therapeutics doses first patients in infigratinib clinical trials
Category: #health  By Mateen Dalal  Date: 2020-03-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

QED Therapeutics doses first patients in infigratinib clinical trials
  • The trial monitors infigratinib in the post-surgery treatment of invasive urothelial carcinoma
     
  • Volunteers with a high risk of cancer recurrence after the surgery are being given FGFR3 genetic alterations

California headquartered pharmaceutical company- Bridge Bio Pharma Inc., has reportedly announced that QED Therapeutics has dosed patients in separate Phase 2 and Phase 3 clinical studies of infigratinib in the treatment of cancers.

Citing reliable sources, during the clinical trial, subjects having invasive urothelial cancer with susceptible FGFR3 genetic alterations who pose a higher risk of relapse following a surgical procedure are being given the treatment.

Reportedly, the Phase 3 PROOF 302 study which is sponsored by QED Therapeutics monitors infigratinib in the post-surgery treatment of invasive urothelial carcinoma – a type of cancer that usually develops in the urinary system.

Another investigator-initiated study is being carried out by Sameek Roychowdhury, M.D., Ph.D, Ohio State University Comprehensive Cancer Center, to understand the use of infigratinib towards the treatment of newly discovered and metastatic solid tumors with FGFR fusions or other alterations.

According to Sumanta Pal, M.D., professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Facility and the PROOF 32 trial lead, many patients suffering from urothelial carcinoma witness a recurrence of cancer within two years of the surgery. These patents are likely to benefit from an oral, post-surgery medication that targets the FGFR3 alterations.  

Notably, the Phase 2 trial at the Ohio State University and other selected centers within the Oncology Research Information Exchange Network will study the efficiency of infigratinib in patients who are diagnosed with metastatic or advanced solid tumors that stand positive for FGFR1-3 gene fusions or other alterations.

Established in 2015, BridgeBio Pharma is a leading pharmaceutical firm that aims at developing life-altering medicines that target genetic diseases at their source.

QED Therapeutics – a subsidiary of BridgeBio Pharma Inc. is a leading biotechnology firm that aims at developing precision medicine for FGFR- related diseases. The company proposes to submit a new drug application with the U.S. F.D.A. for second and later stages cholangiocarcinoma in the year 2020.

 

Source Credits: https://bridgebio.com/news/bridgebio-pharmas-qed-therapeutics-announces-dosing-of-first-patients-in-phase-3-and-phase-2-clinical-trials-of-infigratinib-in-tumors-with-fgfr-genetic-alterations

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...